← Back to Search

Unknown

PF-07265803 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose, in intervals of 0-6, 6-12, 12-24, 24-48, 48-72, 72-96 hours postdose on day 1, and each subsequent 24 hours interval up to discharge (maximum 14 days)
Awards & highlights

Study Summary

The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose, in intervals of 0-6, 6-12, 12-24, 24-48, 48-72, 72-96 hours postdose on day 1, and each subsequent 24 hours interval up to discharge (maximum 14 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose, in intervals of 0-6, 6-12, 12-24, 24-48, 48-72, 72-96 hours postdose on day 1, and each subsequent 24 hours interval up to discharge (maximum 14 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Relative Abundance of PF-07265803 and Its Metabolites in Feces, Expressed as Percentage of Radioactivity
Relative Abundance of PF-07265803 and Its Metabolites in Plasma, Expressed as Percentage of Radioactivity
Relative Abundance of PF-07265803 and Its Metabolites in Urine, Expressed as Percentage of Radioactivity
+3 more
Secondary outcome measures
AUCinf of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma
AUClast of PF-07265803, PF-07327859, PF-07327860 and PF-07327890 in Plasma
Apparent Clearance (CL/F) of PF-07265803 in Plasma
+13 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: PF-07265803Experimental Treatment1 Intervention
PF-07265803 is a p38 inhibitor formulated for oral delivery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07265803
2022
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,570 Previous Clinical Trials
10,915,979 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,476 Previous Clinical Trials
8,092,175 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803
2022. "A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05286281.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top